Tuberculosis (TB) is a global epidemic responsible for 9.6 million new TB cases and 1.5 million deaths in 2014. New TB vaccines are central to the efforts to eliminate the threat of this disease. A vaccine that prevents adolescents and adults from acquiring, developing and transmitting TB would be an innovation with enormous global impact.
To achieve this goal, Aeras, in conjunction with a diverse array of international partners, develops TB vaccines and conducts clinical trials around the world. These efforts include the development of samples and data sets, which are made available at our biorepository.
Note that this program does not provide research funding. Data and specimen resources, however, are provided at no cost to the investigator beyond actual costs incurred for shipping/handling and in the case of special specimen processing requirements.